I could be wrong but not one analyst/journalist/whizz kid had predicted in any analysis used as a basis for investment has discussed using an inflammatory marker to determine the use of any of our therapies, which in my mind means we can use our ‘magic goo’ in conjunction with traditional SOC. My take out is for BP …..as we move from being a threat to being a necessary adjunct to their treatment Now that makes us very investible and irresistible and the investing community better keep up with the science toute suite
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes, page-141
-
- There are more pages in this discussion • 866 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |